|
Gain
from Pain
As the focus shifts from acute to chronic diseases, there
is an increase in revenues of pharmaceutical companies. Arshiya
Khan tracks the growth of this segment
Suven's
ACT partners with VPSCRO
Suven Life Sciences announced that its clinical research division
Asian Clinical Trials (ACT) has entered into a strategic alliance
with VPSCRO, a CRO based in Beijing, China, to conduct clinical
trial services in India, as well as in China.
Orchid
forays into Japan
Orchid announced the formation of its wholly owned subsidiary
in Japan called Orchid Pharma Japan (Orchid Japan).
Intas
and Kwizda complete phase I clinical trial
Intas Biopharmaceuticals Limited (IBPL) and Kwizda Pharma
have jointly completed phase I clinical trial study of Neukine,
biosimilar form of recombinant GCSF.
Glenmark
completes preclinical development of a monoclonal antibody
Glenmark Pharmaceuticals SA (Switzerland), has completed crucial
Investigational New Drug-enabling (IND) preclinical studies
of its monoclonal antibody GBR 500.
Alembic
eyes Rs 2,000 crore revenues
On the occasion of its centenary celebration C R Amin, Chairman
and Managing Director, Alembic, said that the company would
continue to be socially responsible, knowledge driven and
people centric organisation.
DRL
signs definitive agreement with Dow Chemicals
Dr Reddy's Laboratories (DRL) announced that it has entered
into a definitive agreement with the Dow Chemical company
to acquire a portion of Dow Pharma small molecules business
associated with its United Kingdom sites in Mirfield and Cambridge.
Troikaa's
R&D gets DSIR recognition
Troikaa has received recognition for its in-house R&D
facility from the Department Of Scientific and Industrial
Research (DSIR) under the Ministry of Science and Technology.
Showcasing
the 'emerging South'
EXIM bank's annual day lecture presented a platform to discuss
the changing structure of world economy and what role does
the emerging South plays in it. Suja Nair reports
Events
Priority
to create awareness of international standards
It has been three years since United States Pharmacopeia (USP)
came to India. Kumud Sampath, Vice President International,
USP India charts USP India's current projects and future plans
with Viveka Roychowdhury
Indian
companies growing outside the borders of India
Dow Wolff Cellulosics (DWC) is increasing its investments
in India. Philip Pilnik, Global Commercial Director-Pharma
Business, DWC shares more details with Arshiya Khan
|
